Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Tsushima, T. Yokoyama, Y. Ichimura, K. Tatsumi (Chiba, Matsumoto, Japan). A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis. Eur Respir J 2013; 42: Suppl. 57, 2329

Member's Comments

No comment yet.

Related content which might interest you: Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease Source: Eur Respir Rev 2009; 18: 129-132 Year: 2009 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Acute exacerbations of interstitial lung disease Source: Eur Respir Monogr 2016; 74: 117-131 Year: 2016 Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016 Year: 2017 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Does emphysema coexistence with IPF change prognosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013